BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice

• Published in: Haematologica Vol. 108; no. 4; pp. 958 - 968
• Main Authors: Zhou, Xiang, Rasche, Leo, Kortüm, K Martin, Mersi, Julia, Einsele, Hermann
• Format: Journal Article Book Review
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.04.2023; Ferrata Storti Foundation
• Subjects: Antibodies, Bispecific - therapeutic use; B-Cell Maturation Antigen; Biology; Humans; Immunotherapy; Immunotherapy, Adoptive - adverse effects; Multiple Myeloma - drug therapy; Neoplasm Recurrence, Local - drug therapy; Receptors, Chimeric Antigen; Review

The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are bringing new treatment options to patients with relapsed/refractory MM. Currently, B-cell maturation antigen (BCMA) has emerged as the most comm...